Nutrition21 highlights clinical studies at ISSN conference



SADDLE BROOK, NJ. — Nutrition21, LLC presented findings from nooLVL studies at the International Society of Sports Nutrition (ISSN) conference, held in mid-June in Fort Lauderdale, Fla.

The company’s nooLVL ingredient is a patented, non-stimulant nootropic that boosts cognitive performance in gamers. The complex of bonded arginine silicate and inositol was the first nootropic ingredient to be clinically studied in esports athletes in 2019. It now has three clinical studies supporting various cognitive benefits such as improved attention and concentration, enhanced executive function and increased energy. The ingredient may be formulated into a range of products, including ready-to-drink beverages, functional candy and snacks, powders, bars and more, according to the company.

Nutrition21 featured three additional sports nutrition ingredients at the conference: Nitrosigine, Velositol and Chromax. Nitrosigine is a patented complex of bonded arginine silicate. The pre-workout, non-stimulant ingredient promotes nitric oxide production for improved blood flow, focus and energy. Velositol is patented complex of amylopectin and chromium. When used with protein, the post-workout ingredient has been shown to increase strength by accelerating muscle protein synthesis. Chromax is a highly bioavailable form of chromium. The weight management ingredient is supported by 35 human clinical studies affirming its benefits for body composition, appetite control, cognitive health, glucose metabolism and insulin function.

Nutrition21 was a key sponsor for the 19th annual ISSN conference.

“Being able to tap into the sports nutrition audience at ISSN is a huge advantage for us from a sales and research point of view,” said Todd Spear, vice president of sales at the Saddle Brook, NJ-based company.



Source link

Leave a Reply

Your email address will not be published.